Provided by Tiger Fintech (Singapore) Pte. Ltd.

PMV Pharmaceuticals

1.08
-0.0200-1.82%
Post-market: 1.110.0300+2.78%19:28 EDT
Volume:105.66K
Turnover:118.06K
Market Cap:56.09M
PE:-0.95
High:1.14
Open:1.12
Low:1.08
Close:1.10
Loading ...

PMV Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
08 Nov 2024

Optimistic Buy Rating for PMV Pharmaceuticals Driven by Strategic Clinical Trials and Strong Financial Position

TIPRANKS
·
07 Nov 2024

PMV Pharma Q3 EPS $(0.37) Misses $(0.35) Estimate

Benzinga
·
07 Nov 2024

PMV Pharmaceuticals: Cash, Cash Equivalents, & Marketable Securities of $197.9 Mln as Sept 30, Providing Expected Cash Runway to End of 2026

THOMSON REUTERS
·
07 Nov 2024

PMV Pharmaceuticals Qtrly Net Loss per Share $0.37

THOMSON REUTERS
·
07 Nov 2024

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

THOMSON REUTERS
·
07 Nov 2024

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

GlobeNewswire
·
07 Nov 2024

PMV Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

BUZZ-Citi sees lack of immediate upside catalyst for Premier after Myer deal

Reuters
·
31 Oct 2024

PMV Pharmaceuticals Inc - Discontinues Enrollment in Phase 1B Combination Arm of Pynnacle Trial

THOMSON REUTERS
·
23 Oct 2024

PMV Pharmaceuticals Inc - Collaborates With Mdacc and Msk for Phase 1B Study in Aml/Mds

THOMSON REUTERS
·
23 Oct 2024

PMV Pharmaceuticals Inc - Enrollment on Track in Phase 2 Pynnacle Trial, Interim Analysis by Mid-2025

THOMSON REUTERS
·
23 Oct 2024

PMV Pharmaceuticals Provides a Progress Update on Pynnacle Clinical Trial

THOMSON REUTERS
·
23 Oct 2024

PMV Pharmaceuticals Inc - to Provide Interim Data by Mid-2025, Nda Submission by End of 2026

THOMSON REUTERS
·
23 Oct 2024

PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

GlobeNewswire
·
23 Oct 2024